Key Takeaways
- President Trump's executive order on lowering drug prices endorses legislation lengthening the period of time small molecules have on the market before they could be...
President Trump endorsed legislation extending the statutory timeline before small molecule drugs can be subject to the Medicare price negotiation, a high priority for biopharma, in an
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?